Cracking Down On Silicone Implants
The controversy over silicone-filled breast implants has taken a new turn. On Aug. 22, the Food & Drug Administration notified three manufacturers that data they had submitted for safety reviews was insufficient. The three are Bioplasty, California doctor Joseph F. Cavon, and Bristol-Myers Squibb's Surgitek unit. The ruling could signal the end of their implants. Surgitek stopped marketing its implant in April after the FDA found that foam used in its manufacture could decompose into a carcinogenic material.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Fed Raises Rates, Eyes Three 2018 Hikes as Yellen Era Nears End
- This Electric Truck Will Probably Beat Tesla’s to Market
- These Guys Want to Lend You Money Against Your Bitcoin
- Famed Short-Seller Jim Chanos Says Tesla Headed for ‘Brick Wall’
- Bitcoin Points Way to ‘Massive Change’ for Commodity Businesses